Inosamin (Eplerenone)

Eplerenone blocks mineralocorticoid receptors in the kidney, preventing aldosterone from promoting sodium and water reabsorption. This leads to increased sodium excretion, retention of potassium, and a reduction in blood‑volume‑related pressure, helping to control hypertension and lessen cardiac stress.

The appropriate dose of Inosamin is determined by the prescribing clinician based on the patient’s medical condition, kidney function, and potassium levels. Dosage adjustments are made during treatment to achieve therapeutic goals while minimizing risk.

The pregnancy category for eplerenone is unknown, and safety has not been established. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and a healthcare professional should be consulted.

To order Inosamin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both eplerenone (Inosamin) and spironolactone are mineralocorticoid receptor antagonists, but eplerenone is more selective for the aldosterone receptor, resulting in fewer anti‑androgenic side effects such as gynecomastia. Dosing and monitoring principles are similar, though individual response may vary.

Inosamin tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Inosamin is taken orally, usually with or without food, as directed by a healthcare professional. Swallow the tablet whole with a full glass of water and follow the prescribed schedule to maintain consistent blood levels.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and worsening renal function. Patients should be alert for symptoms such as muscle weakness, irregular heartbeat, or sudden decrease in urine output and seek medical attention promptly.

Inosamin is contraindicated in individuals with known hypersensitivity to eplerenone, existing hyperkalemia, or severe renal impairment. Caution is also advised for patients taking other potassium‑increasing agents or those with uncontrolled electrolyte disorders.